Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 25 , ISSUE 11 ( November, 2021 ) > List of Articles

CASE REPORT

Cutaneous Mucormycosis in a Patient of Severe COVID-19 Pneumonia: A Rarer than Rare Case Report

Rahul R Tambe, Anupa Hinduja, Suchithra Sunil, Ami Varaiya, Amol Joshi

Citation Information : Tambe RR, Hinduja A, Sunil S, Varaiya A, Joshi A. Cutaneous Mucormycosis in a Patient of Severe COVID-19 Pneumonia: A Rarer than Rare Case Report. Indian J Crit Care Med 2021; 25 (11):1318-1319.

DOI: 10.5005/jp-journals-10071-24026

License: CC BY-NC 4.0

Published Online: 16-11-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Abstract

Coronavirus disease-2019 (COVID-19)-associated mucormycosis is on the rise in the Indian subcontinent. We report a unique case of cutaneous mucormycosis in a case of newly diagnosed young diabetic patient with severe COVID-19 pneumonia with post-COVID lung fibrosis. Neither did he have any preceding trauma or wound, nor was there any evidence of any secondary dissemination. Cutaneous mucormycosis without evidence of either is unheard off. Possible risk factors in this case were multiple bacterial secondary infections with the use of higher antibiotics, use of voriconazole for possible aspergillosis, and steroid use.

HTML PDF Share
  1. Zhang H, Zhang Y, Wu J, Li Y, Zhou X, Li X, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect 2020;9(1):1958–1964. DOI: 10.1080/22221751.2020.1812437.
  2. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis 2021;27(9):2349–2359. DOI: 10.3201/eid2709.210934.
  3. WHO. Mucormycosis. Who.Int. WHO – South East Asia – India; 2021. Available from: https://www.who.int/india/emergencies/coronavirus-disease-(covid-19)/mucormycosis.
  4. Castrejón-Pérez AD, Miranda I, Welsh O, Welsh EC, Ocampo-Candiani J. Cutaneous mucormycosis. An Bras Dermatol 2017;92(3):304–311. DOI: 10.1590/abd1806-4841.20176614.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.